Posted inStock Dow futures slip 214 points amid Fed jitters: 5 things to know before Wall Street opens Dow futures were under pressure on Friday, falling about 214 points, roughly 0.5% as investors… November 14, 2025 Posted inStock How Caterpillar is emerging as an AI giant: Wells Fargo Caterpillar shares may still have room to climb, according to Wells Fargo, which initiated coverage… November 14, 2025 Posted inStock Goldman Sachs says this AI name is a better pick than Palantir stock for 2026 Palantir Technologies Inc (NASDAQ: PLTR) has pulled back in recent days amidst a broader sell-off… November 14, 2025 Posted inStock MSTR stock price analysis as mNAV drops below 1 The MSTR stock price has collapsed this year, moving from the year-to-date high of $456… November 14, 2025 Posted inStock The next wave of AI-driven cost cuts: Vista and Meta send clear signals this week The private equity and big tech playbooks are converging on a singular strategy: replace expensive… November 14, 2025 Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inStock How Caterpillar is emerging as an AI giant: Wells Fargo Caterpillar shares may still have room to climb, according to Wells Fargo, which initiated coverage… November 14, 2025 Posted inStock Goldman Sachs says this AI name is a better pick than Palantir stock for 2026 Palantir Technologies Inc (NASDAQ: PLTR) has pulled back in recent days amidst a broader sell-off… November 14, 2025 Posted inStock MSTR stock price analysis as mNAV drops below 1 The MSTR stock price has collapsed this year, moving from the year-to-date high of $456… November 14, 2025 Posted inStock The next wave of AI-driven cost cuts: Vista and Meta send clear signals this week The private equity and big tech playbooks are converging on a singular strategy: replace expensive… November 14, 2025 Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inStock Goldman Sachs says this AI name is a better pick than Palantir stock for 2026 Palantir Technologies Inc (NASDAQ: PLTR) has pulled back in recent days amidst a broader sell-off… November 14, 2025 Posted inStock MSTR stock price analysis as mNAV drops below 1 The MSTR stock price has collapsed this year, moving from the year-to-date high of $456… November 14, 2025 Posted inStock The next wave of AI-driven cost cuts: Vista and Meta send clear signals this week The private equity and big tech playbooks are converging on a singular strategy: replace expensive… November 14, 2025 Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inStock MSTR stock price analysis as mNAV drops below 1 The MSTR stock price has collapsed this year, moving from the year-to-date high of $456… November 14, 2025 Posted inStock The next wave of AI-driven cost cuts: Vista and Meta send clear signals this week The private equity and big tech playbooks are converging on a singular strategy: replace expensive… November 14, 2025 Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inStock The next wave of AI-driven cost cuts: Vista and Meta send clear signals this week The private equity and big tech playbooks are converging on a singular strategy: replace expensive… November 14, 2025 Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inStock Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion… November 14, 2025
Posted inPolitics Trump’s energy chief to unleash Gulf drilling with major rule change Interior Secretary Doug Burgum on Friday will update a Biden-era federal rule regarding energy development… May 2, 2025
Posted inPolitics Buttigieg ‘got nothing done,’ Duffy declares: ‘Pete appears unburdened by no longer being a cabinet secretary’ Transportation Sec. Sean Duffy suggested that the department has accomplished more during the first 100… May 2, 2025
Posted inEconomy Consumers are not lovin’ it: McDonald’s has its worst quarter since 2020 McDonald’s reported its worst quarterly sales for the United States since the height of the… May 2, 2025
Posted inEconomy Tesla denies report that the EV maker is looking to replace Elon Musk Shares of Tesla were flat in premarket trading Thursday after the EV maker denied a Wall Street… May 2, 2025
Posted inEconomy Amazon is stepping up to fill a gap in Hollywood’s movie slate Tech is saving Hollywood — though not in the way you might think. Back in… May 2, 2025
Posted inEconomy Nvidia says Anthropic is telling ‘tall tale’ in its defense of U.S. AI chip restrictions on China Nvidia blasted Anthropic Thursday in a rare public clash over artificial intelligence policy with U.S. chip export restrictions set to take effect.… May 2, 2025
Posted inStock Will the Rolls-Royce share price hit 1,000p after its earnings? The Rolls-Royce share price held steady on Thursday after the company published its financial results… May 1, 2025
Posted inStock Europe markets open: FTSE 100 poised higher; focus on UK amid European closures London’s FTSE 100 index is expected to open higher on Thursday, looking to extend an… May 1, 2025
Posted inStock Can Lloyds share price surge to 100p after its earnings? Lloyds share price is hovering at its highest level in over 17 years as the… May 1, 2025
Posted inStock Why the Starbucks CEO still backs SBUX stock despite earnings slump Starbucks Corp (NASDAQ: SBUX) Q2 financials are not at all indicative of how the company’s… May 1, 2025